[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-2-phenylbutan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-2-phenylbutan-2-yl]carbamate
• 化学式: C₂₅H₃₅N₃O₆S
• 分子量: 505.6
• InChiKey: MPSCHJHDSZVDCD-PWWKTKHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• EP2969006A1
  申请人：——

  公开号：EP2969006A1

  公开（公告）日：2016-01-20
• COMPOSITIONS AND METHODS FOR IDENTIFYING LATENTLY INFECTED CELLS
  申请人：The J. David Gladstone Institutes

  公开号：EP3033087A2

  公开（公告）日：2016-06-22
• [EN] COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER UNE INFECTION PAR UN VIRUS D'IMMUNODÉFICIENCE
  申请人：DAVID GLADSTONE INST

  公开号：WO2014151771A1

  公开（公告）日：2014-09-25

  The present disclosure provides an interfering, conditionally replicating human immunodeficiency virus (HIV) construct; infectious particles comprising the constructs; and compositions comprising the construct or the particle. The constructs, particles, and compositions are useful in methods of reducing HIV viral load in an individual, which methods are also provided.
• [EN] COMPOSITIONS AND METHODS FOR IDENTIFYING LATENTLY INFECTED CELLS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'IDENTIFIER DES CELLULES INFECTÉES DE MANIÈRE LATENTE.
  申请人：DAVID GLADSTONE INST

  公开号：WO2015023811A2

  公开（公告）日：2015-02-19

  The present disclosure provides for recombinant nucleic acids, and cells and virions comprising the recombinant nucleic acids, that can be used to identify, isolate, and/or purify cells latently infected with immunodeficiency virus. A subject recombinant nucleic acid includes (a) a first nucleotide sequence encoding a first reporter polypeptide that produces a first detectable signal, where the first nucleotide sequence is operably linked to an immunodeficiency virus promoter and is translated as an early gene; and (b) a second nucleotide sequence encoding a second reporter polypeptide that produces a second detectable signal that is distinguishable from the first detectable signal, where the second nucleotide sequence is operably linked to a non-immunodeficiency virus promoter. In some aspects, the first and second nucleotide sequences are both positioned between a shared 5' long terminal repeat (LTR) and a shared 3' LTR. Also provided are related methods.
• [EN] COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS VIRALES PAR UN CORONAVIRUS ASSOCIÉ AU SYNDROME RESPIRATOIRE
  申请人：SOM INNOVATION BIOTECH S A

  公开号：WO2021209563A1

  公开（公告）日：2021-10-21

  The present invention relates to a compound selected from the group consisting of cynarine, eravacycline and prexasertib or a pharmaceutically acceptable salt thereof, preferably eravacycline or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by coronavirus selected from the group consisting of MERS-CoV, SARS-CoV and SARS-CoV-2 virus, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.